Lung Cancer – LCS & IPN
Median’s portfolio for Lung Cancer Diagnosis:
Lack of diagnostic accuracy is a major hurdle for screening program implementation and adherence
Lung cancer prognosis is the poorest of all common cancers, largely due to a high proportion of cases being detected at an advanced stage
A stage shift in lung cancer diagnosis would have a dramatic impact on lowering overall mortality
Median’s eyonis® LCS
Unrivalled AI/ML Software as Medical Device (SaMD) enabling early lung cancer diagnosis with unprecedented performance
End-to-end AI/ML tech-based CADe CADx for early diagnosis in lung cancer screening programs
Indicated for the detection, localization, and characterization of pulmonary nodules into suspicious/malignant
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications
Liver cancer
Very early hepatocellular carcinoma (HCC)
About eyonis®
Early diagnosis & treatment of cancer
Latest news
Webcast
eyonis® LCS successfully meets primary endpoint in RELIVE pivotal study: next steps towards marketing authorizations
KOL webinar
The eyonis® Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying
PRESS RELEASE
eyonis® Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions
